Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.

Advertisement

Related Content

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix
Biopharma Dealmaking Quarterly Statistics, Q3 2014
European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?
Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus
Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
With Novartis Ending RNAi Research Partnership, Alnylam Trims Workforce

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel